Rachel Lei has joined Aldevron as its new General Counsel and Corporate Secretary. Lei will advise the Board of Directors and CEO on issues of overarching importance to Aldevron and will assist in setting and implementing Aldevron’s overall strategic direction , building and overseeing Aldevron’s legal department to ensure that its legal function operates as a true business partner.
Aldevron, the leading plasmid DNA, proteins and mRNA manufacturing company, is pleased to announce the hiring of Kenneth (Ken) Bonnell as Vice President of Quality and Regulatory Affairs.
Aldevron, the leading plasmid DNA manufacturing company, has expanded its leadership team by appointing Cynthia Biffert as Vice President of its GMP Nucleic Acids Business Unit (NABU).
Aldevron is excited to announce our partnership with MEEI to support its manufacturing of an experimental vaccine for clinical studies for its AAVCOVID vaccine program.
Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins, mRNA and antibodies for the biotech industry, has hired Vijay Surapaneni as its Vice President of Biomanufacturing Operations. This is a new position and is a part of the senior management team.
FARGO, N.D. (February 12, 2019)—Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins, mRNA and antibodies to the biotech industry, announced today the addition of DasherGFP® (green fluorescent protein) mRNA to its off-the-shelf, product portfolio.
In June of 2019, Aldevron announced its massive 14-acre campus expansion. The construction began with a groundbreaking ceremony in August of 2019, launching the buildout of the campus’ second GMP manufacturing facility. This 189,000 square-foot, two-story building is slated to increase Aldevron’s GMP and GMP-Source production capacity up to 10 times its current output. In December of 2019, a major milestone was reached when structural steel beams were installed (pictured).
Aldevron officially broke ground on its 14-acre campus expansion at its global headquarters in Fargo, North Dakota, August 19. Three buildings are planned, with construction of its next GMP manufacturing facility starting first.
• EQT to partner with founder and CEO Michael Chambers,
as well as TA Associates, to support Aldevron on its future growth journey
Aldevron has named Brian Walters, President of its antibody business unit and Tom Foti President of its protein business unit.
